

Date: 15<sup>th</sup> March, 2016

To,

1. **Gilead Sciences, Inc.**  
333 Lakeside Drive, Foster City,  
California 94404, USA
  
2. **Medicines Patent Pool**  
Chemin Louis-Dunant 17,  
1202 Geneva, Switzerland

**Sub.:** Termination of Tenofovir Disoproxil Fumarate ("TDF")

**Ref.:** Third Amended and Restated License Agreement ("**Agreement**") dated March 15<sup>th</sup>, 2016 executed by and between Gilead Sciences, Inc. ("**Gilead**"), the Medicines Patent Pool ("**MPP**") and Emcure Pharmaceuticals Limited ("**Emcure**").

Pursuant to Clause 10.5 of the Agreement, Emcure hereby terminates the license granted for TDF by providing this termination notice. Such termination shall be effective immediately upon the receipt of this notice by Gilead and MPP.

On termination, all clauses pertaining to TDF shall immediately cease to be in effect.

Subject to the aforesaid, all other terms and conditions of the Agreement shall remain enforceable and unchanged.

Yours truly,

For **Emcure Pharmaceuticals Limited**

Sign :  \_\_\_\_\_

**Name : Balaji U. D.**

**Title : Senior Director - Global HIV/AIDS Initiatives**

**Emcure Pharmaceuticals Limited**

**Registered Office :** Emcure House, T-184, M.I.D.C., Bhosari, Pune - 411026. INDIA

Phone Nos. : + 91 20 - 27120084, 30610000, 40700000 Fax No.: 91 20 - 30610111

E-mail : corporate@emcure.co.in Website : www.emcure.co.in CIN : U24231PN1981PLC024251